Holen Sie sich die Stockscreener-App
264.49
0.19%
0.49
Handel nachbörslich:
264.49
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$264.00
Offen:
$262.48
24-Stunden-Volumen:
1.51M
Relative Volume:
0.51
Marktkapitalisierung:
$142.17B
Einnahmen:
$32.53B
Nettoeinkommen (Verlust:
$4.23B
KGV:
18.80
EPS:
14.07
Netto-Cashflow:
$6.28B
1W Leistung:
-0.55%
1M Leistung:
-10.20%
6M Leistung:
-16.87%
1J Leistung:
-6.92%
1-Tages-Spanne:
$261.36
$264.55
1-Wochen-Bereich:
$253.30
$269.61
52-Wochen-Spanne:
$253.30
$346.85
Amgen Inc Stock (AMGN) Company Profile
Firmenname
Amgen Inc
Sektor
Telefon
(805)447-1000
Adresse
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Vergleichen Sie AMGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
264.49 | 142.17B | 32.53B | 4.23B | 6.28B | 7.81 |
|
LLY
Lilly Eli Co
|
795.67 | 715.56B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
87.37 | 388.07B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
145.85 | 351.15B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
180.00 | 318.09B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
99.45 | 251.57B | 63.17B | 12.15B | 14.84B | 4.77 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-14 | Herabstufung | Truist | Buy → Hold |
| 2024-09-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Hochstufung | Truist | Hold → Buy |
| 2023-10-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-17 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-24 | Bestätigt | Oppenheimer | Outperform |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Bestätigt | Truist | Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Underperform |
| 2022-10-31 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-09 | Bestätigt | Barclays | Equal Weight |
| 2022-02-09 | Bestätigt | Jefferies | Buy |
| 2022-02-09 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-09 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-09-23 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Eingeleitet | Daiwa Securities | Buy |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Hochstufung | Truist | Hold → Buy |
| 2020-10-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Herabstufung | Truist | Buy → Hold |
| 2020-10-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Fortgesetzt | Guggenheim | Neutral |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-03-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-17 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-05-23 | Hochstufung | Citigroup | Neutral → Buy |
Alle ansehen
Amgen Inc Aktie (AMGN) Neueste Nachrichten
Here's Why Amgen (AMGN) Gained But Lagged the Market Today - Yahoo Finance
Burkitt Lymphoma Global Clinical Trials Review 2024: Clinical Trials by Region, Country, Trial Status, Trial Phase, Sponsor Type and End Point Status - GlobeNewswire Inc.
Amgen, Lilly Sue HHS Over Clinics in Drug Discount Program - Bloomberg Law
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know - Yahoo Finance
Cell Therapy Market Overall Study Report 2024-2031 | Amgen Inc., - openPR
Novo obesity data positive for Eli Lilly and Amgen, says UBS - Yahoo Finance
Amgen Inc. stock rises Friday, still underperforms market - MarketWatch
What's Going On With Amgen Stock On Friday? - Benzinga
Amgen (AMGN) Rises Over 3% Amid Novo Nordisk Trial Results - GuruFocus.com
Amgen (NASDAQ:AMGN) Shares Gap UpTime to Buy? - MarketBeat
Principal Financial Group Inc. Increases Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Amgen (NASDAQ:AMGN) Reaches New 1-Year LowTime to Sell? - MarketBeat
Amgen stock touches 52-week low at $257.77 amid market shifts By Investing.com - Investing.com South Africa
Amgen stock touches 52-week low at $257.77 amid market shifts - Investing.com Australia
Why Is Amgen Inc. (AMGN) Among the Best Dividend Stocks to Invest In? - Insider Monkey
Herceptin Biosimilar Market Future Business Opportunities - openPR
Amgen's SWOT analysis: stock poised for growth amid obesity market potential - Investing.com
Amgen Hit With $50M Infringement Verdict Over Leukemia Drug - Law360
Amgen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Amgen hit with $50.3 mln US verdict in cancer drug patent lawsuit - Reuters
Amgen Owes Lindis $50 Million for Blincyto’s Patent Infringement - Bloomberg Law
Amgen (NASDAQ:AMGN) Stock Rating Lowered by StockNews.com - MarketBeat
Biologics Market to See Booming Growth 2024-2031 | AbbVie Inc., - openPR
Amgen (AMGN) Stock Moves -0.21%: What You Should Know - Yahoo Finance
Amgen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Is Amgen Inc. (AMGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? - Insider Monkey
KRAS Inhibitors Market Top Companies StudyAmgen, Boehringer - openPR
Viridian taking on Amgen in TED market - BioCentury
Viridian Continues Building Case For Veligrotug In TED - Citeline News & Insights
Amgen Inc. stock outperforms competitors despite losses on the day - MarketWatch
Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen - Yahoo! Voices
Amgen's SWOT analysis: obesity program drives stock outlook - Investing.com
How Much Would It Take To Earn $100 A Month From Amgen Stock - Yahoo Finance
Amgen's (NASDAQ:AMGN) investors will be pleased with their favorable 34% return over the last three years - Simply Wall St
Amgen's (NASDAQ:AMGN) Dividend Will Be Increased To $2.38 - Simply Wall St
Amgen Inc. (NASDAQ:AMGN) Shares Bought by Franklin Resources Inc. - MarketBeat
World Investment Advisors LLC Raises Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Dow's 112-point fall led by losses in NVIDIA Corp., Amgen shares - MarketWatch
Amgen to build $1B North Carolina pharmaceutical plant - Manufacturing Dive
Asset Advisors Investment Management LLC Boosts Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Synovus Financial Corp - MarketBeat
Virtu Financial LLC Takes Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Ten Years of BLINCYTO® (blinatumomab): Celebrating the History, Impact and Future - Amgen
Wilmington Savings Fund Society FSB Grows Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Why Amgen (AMGN) is a Top Growth Stock for the Long-Term - Yahoo Finance
Tudor Financial Inc. Purchases New Shares in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Morse Asset Management Inc Invests $806,000 in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Why Amgen Inc. (AMGN) Is the Best Safe Stock to Buy According to Analysts? - Insider Monkey
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Invst LLC - MarketBeat
Finanzdaten der Amgen Inc-Aktie (AMGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):